Samuel Ejadi

3.4k total citations · 1 hit paper
34 papers, 1.6k citations indexed

About

Samuel Ejadi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Samuel Ejadi has authored 34 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Samuel Ejadi's work include Cancer Immunotherapy and Biomarkers (12 papers), Immunotherapy and Immune Responses (7 papers) and Prostate Cancer Treatment and Research (6 papers). Samuel Ejadi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Immunotherapy and Immune Responses (7 papers) and Prostate Cancer Treatment and Research (6 papers). Samuel Ejadi collaborates with scholars based in United States, South Korea and Canada. Samuel Ejadi's co-authors include Sanatan Saraf, Roger B. Cohen, Sarina A. Piha‐Paul, Aaron R. Hansen, Emilie M.J. van Brummelen, John M. Wallmark, Patrick A. Ott, Caroline Even, Pradeep Thanigaimani and Carlos Gomez‐Roca and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Samuel Ejadi

32 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

2017 300 citations Chiun Hsu, Se‐Hoon Lee et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samuel Ejadi United States	16	1.1k	503	442	393	303	34	1.6k
Fernando Concha‐Benavente United States	19	1.1k 1.0×	281 0.6×	688 1.6×	267 0.7×	142 0.5×	31	1.4k
Jonathan J. Havel United States	13	1.9k 1.8×	683 1.4×	1.1k 2.4×	825 2.1×	222 0.7×	14	2.7k
Marc Oliva Spain	12	519 0.5×	271 0.5×	158 0.4×	472 1.2×	141 0.5×	41	1.2k
Vanessa Deschoolmeester Belgium	24	1.0k 1.0×	396 0.8×	310 0.7×	676 1.7×	185 0.6×	44	1.8k
Nicolas Sirtaine Belgium	17	2.2k 2.0×	484 1.0×	1.0k 2.3×	546 1.4×	134 0.4×	34	2.9k
Mark L. Levitt United States	16	1.1k 1.0×	464 0.9×	164 0.4×	799 2.0×	216 0.7×	43	1.9k
Philipp Lohneis Germany	19	643 0.6×	169 0.3×	300 0.7×	265 0.7×	182 0.6×	57	1.1k
Beata Schlichtholz Poland	13	767 0.7×	137 0.3×	235 0.5×	549 1.4×	172 0.6×	18	1.3k
Chit Chow Hong Kong	21	646 0.6×	568 1.1×	117 0.3×	534 1.4×	197 0.7×	53	1.4k
Gail Eckhardt United States	12	900 0.8×	230 0.5×	116 0.3×	850 2.2×	232 0.8×	20	1.6k

Countries citing papers authored by Samuel Ejadi

Since Specialization

Citations

This map shows the geographic impact of Samuel Ejadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Ejadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Ejadi more than expected).

Fields of papers citing papers by Samuel Ejadi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Ejadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Ejadi. The network helps show where Samuel Ejadi may publish in the future.

Co-authorship network of co-authors of Samuel Ejadi

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Ejadi. A scholar is included among the top collaborators of Samuel Ejadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Ejadi. Samuel Ejadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dayyani, Farshid, et al.. (2022). A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. Medical Oncology. 39(8). 102–102.

Fang, Bin, Stephanie Zhao, Quy Nguyen, et al.. (2020). Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. Scientific Reports. 10(1). 8867–8867. 25 indexed citations

Mahipal, Amit, Samuel Ejadi, Sacha Gnjatic, et al.. (2019). First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunology Immunotherapy. 68(7). 1211–1222. 22 indexed citations

Cho, Byoung Chul, Alexander Drilon, Robert C. Doebele, et al.. (2019). Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).. Journal of Clinical Oncology. 37(15_suppl). 9011–9011. 60 indexed citations

Nemunaitis, John, Annie Young, Samuel Ejadi, et al.. (2018). Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 81(3). 529–537. 16 indexed citations

Hansen, Aaron R., Christophe Massard, Patrick A. Ott, et al.. (2018). Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Annals of Oncology. 29(8). 1807–1813. 260 indexed citations

Ott, Patrick A., Sarina A. Piha‐Paul, Pamela N. Münster, et al.. (2017). Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Annals of Oncology. 28(5). 1036–1041. 164 indexed citations

Hsu, Chiun, Se‐Hoon Lee, Samuel Ejadi, et al.. (2017). Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. Journal of Clinical Oncology. 35(36). 4050–4056. 300 indexed citations breakdown →

O’Neil, Bert H., John M. Wallmark, David Lorente, et al.. (2017). Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS ONE. 12(12). e0189848–e0189848. 221 indexed citations

10.

Morris, Michael J., Nicholas J. Vogelzang, Oliver Sartor, et al.. (2016). Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC): Study update. Annals of Oncology. 27. vi249–vi249. 3 indexed citations

11.

Hansen, Aaron R., Christophe Massard, Naomi B. Haas, et al.. (2016). Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study. Annals of Oncology. 27. vi247–vi247. 36 indexed citations

12.

Morris, Michael J., Daniel P. Petrylak, Oliver Sartor, et al.. (2016). Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). 2586–2586. 1 indexed citations

13.

Hsu, Chih‐Hung, Seung‐Hoon Lee, Samuel Ejadi, et al.. (2015). 315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Annals of Oncology. 26. ix93–ix93. 13 indexed citations

14.

Millis, Sherri Z., Samuel Ejadi, & Michael J. Demeure. (2015). Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy. SHILAP Revista de lepidopterología. 7. BIC.S34292–BIC.S34292. 8 indexed citations

15.

Mahipal, Amit, Kunle Odunsi, Sacha Gnjatic, et al.. (2015). A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1.. Journal of Clinical Oncology. 33(15_suppl). 3073–3073. 3 indexed citations

16.

Piha‐Paul, Sarina A., Pamela N. Münster, Michael J. Pishvaian, et al.. (2015). 500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. European Journal of Cancer. 51. S102–S102. 12 indexed citations

17.

Sekulić, Aleksandar, Paul Haluska, Arlo J. Miller, et al.. (2008). Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape. Mayo Clinic Proceedings. 83(7). 825–846. 90 indexed citations

18.

Perales, Miguel‐Angel, Jianda Yuan, Humilidad F. Gallardo, et al.. (2008). Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma. Molecular Therapy. 16(12). 2022–2029. 76 indexed citations

19.

Ejadi, Samuel, et al.. (2000). Diagnostic Dilemmas in Oncology. Journal of Clinical Oncology. 18(17). 3187–3188. 3 indexed citations

20.

Benasutti, Matt, Samuel Ejadi, Marc Whitlow, & Edward L. Loechler. (1988). Mapping the binding site of aflatoxin B1 in DNA: systematic analysis of the reactivity of aflatoxin B1 with guanines in different DNA sequences. Biochemistry. 27(1). 472–481. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact